603 related articles for article (PubMed ID: 28379469)
1. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome.
Scotti L; Di Pietro M; Pascuali N; Irusta G; I de Zúñiga ; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F
Mol Hum Reprod; 2016 Dec; 22(12):852-866. PubMed ID: 27645281
[TBL] [Abstract][Full Text] [Related]
3. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
4. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome.
Pascuali N; Scotti L; Oubiña G; de Zúñiga I; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F
Mol Hum Reprod; 2020 Aug; 26(8):585-600. PubMed ID: 32467982
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
[TBL] [Abstract][Full Text] [Related]
7. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
[TBL] [Abstract][Full Text] [Related]
8. Effect and underlying mechanism of Bu-Shen-An-Tai recipe on ovarian apoptosis in mice with controlled ovarian hyperstimulation implantation dysfunction.
Ma WW; Xiao J; Song YF; Ding JH; Tan XJ; Song KK; Zhang MM
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):401-406. PubMed ID: 28585136
[TBL] [Abstract][Full Text] [Related]
9. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
10. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death.
Li F; Turan V; Lierman S; Cuvelier C; De Sutter P; Oktay K
Hum Reprod; 2014 Jan; 29(1):107-13. PubMed ID: 24221908
[TBL] [Abstract][Full Text] [Related]
12. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome.
Scotti L; Abramovich D; Pascuali N; Irusta G; Meresman G; Tesone M; Parborell F
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():392-401. PubMed ID: 25151950
[TBL] [Abstract][Full Text] [Related]
13. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
[TBL] [Abstract][Full Text] [Related]
15. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
[TBL] [Abstract][Full Text] [Related]
16. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
[TBL] [Abstract][Full Text] [Related]
17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
18. Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.
Bishop CV; Lee DM; Slayden OD; Li X
J Ovarian Res; 2017 Jul; 10(1):41. PubMed ID: 28683759
[TBL] [Abstract][Full Text] [Related]
19. The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model.
Ozgur S; Oktem M; Altinkaya SO; Oktem EO; Cenksoy C; Erdem O; Elbeg S; Helvaci A; Erdem A; Erdem M
Taiwan J Obstet Gynecol; 2018 Jun; 57(3):383-388. PubMed ID: 29880170
[TBL] [Abstract][Full Text] [Related]
20. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
